Table 2. Description of patients and outcomes of treatment in the included studies.

Reference (Author)	Enrolled participants (n)	Enrolled children n (%)	Age of enrolled children (years old; range*)	Leishmania species (%)	Definition of cure	Cure in children ITT n/N (%)	Cure in adults ITT n/N (%)	Cure in children PP n/N (%)	Cure in adults PP n/N (%)
ACL
Castro MdM, et al.[5]	60	30 (50)	2–12	L.(V) panamensis (66.7); L.(V) braziliensis (3.3); Not isolated (30).	Complete re-epithelialization and absence of inflammatory signs for all lesions at day 210.	Miltefosine: 24/30 (80)	Miltefosine: 28/30 (93.3)	Miltefosine: 24/29 (82.7)	Miltefosine: 28/28 (100)
Chrusciak-T A, et al.[23]	90	30 (33.3)	4–12	L.(V) guyanensis (93.3); L.(V) braziliensis (3.3); L.(V) lainsoni (3.3).	Complete epithelialization of all ulcers and complete disappearance of inflammatory induration from all lesions at 6 months follow-up visit.	No data	No data	Miltefosine: 12/19 (63.1) Meglumine antimoniate: 5/9 (55.5).	Miltefosine: 28/37 (75.7) Meglumine antimoniate: 10/19 (52.6)
Machado P, et al.[24]	90	32 (35.5)	4–12	L.(V) braziliensis (45.5).	Lesions with complete re-epithelialization, without raised borders, infiltrations or crusts at 6 months after the end of therapy.	Miltefosine: 15/22 (68.2) Meglumine antimoniate: 7/10 (70)	Miltefosine: 30/38 (78.9) Meglumine antimoniate: 9/20 (45).	No data	No data
Palacios R, et al.[7]	136	86 (63.2)	≤14**	L.(V) panamensis (95.5); L.(V) braziliensis (4.5) †	Initial clinical response (complete re-epithelialization and absence of inflammatory signs of all lesions at 13 weeks after initiation of treatment) and no relapses of lesions between 13 and 52 weeks of follow-up.	Meglumine antimoniate 10 days: 0–4 y/o: (17) 5–14 y/o: (53) 20 days: 0–4 y/o: (24) 5–14 y/o: (68)	Meglumine antimoniate 10 days: ≥15 y/o: (61) 20 days: ≥15 y/o: (69)	Meglumine Antimoniate 10 days: 0–4 y/o: 1/9 (11) 5–14 y/o: 14/21 (67) 20 days: 0–4 y/o: 2/8 (25) 5–14 y/o: 12/16 (75)	Meglumine Antimoniate 10 days: >14 y/o: 13/16 (81) 20 days: >14 y/o: 10/12 (83)
Rubiano LC, et al.[22]	116	116 (100)	2–12	L.(V) panamensis (71.7); L.(V) guyanensis (26.6); L. (V) braziliensis (1.7)	Initial clinical therapeutic response (complete re-epithelialization and absence of inflammatory signs of all lesions) attained by week 13 and maintained until week 26 without the appearance of new lesions.	Miltefosine: 48/58 (82.8) a Meglumine antimoniate: 40/58 (69) a	Not applicable	Miltefosine: 48/55 (87.3) a Meglumine antimoniate: 40/56 (71.4) a	Not applicable
OWCL
Jaffar H. [25]	62	32 (51.6)	3–11	Not reported. Author describes L.(L) tropica. and L.(L) major as endemic species in the region.	Complete healing of lesions at the end of three months.	No data	No data	Rifampicin: 15/18 (83.4) Placebo: 2/3 (66.6).	Rifampicin: 6/16 (37.5) Placebo: 1/4 (25).
Layegh P, et al. 2009[26]	79	79 (100)	Cryotherapy: 6.8 (3.4) *** Intralesional MA: 6.2(3.4) ***	Not reported. Authors describe L.(L) tropica as endemic specie in the region.	Full re-epithelialization of lesions; disappearance of edema, induration, and other signs of inflammation; and a negative direct skin smear result at six months after treatment.	Cryotherapy: 15/40 (37.5) a Intralesional meglumine antimoniate: 26/39 (66.7) a	Not applicable	Cryotherapy: 15/36 (41.7) a Intralesional meglumine antimoniate: 26/36 (72.3) a	Not applicable
Layegh P, et al. 2011[27]	112	56 (50)	≤15**	Not reported. Authors describe L.(L) tropica as endemic species in the region.	Full re-epithelialization of ulcers and 100% decrease of induration size for papulo-plaque or nodular lesions, at 45 days after treatment.	Meglumine antimoniate: 18/56 (32.1) a	Meglumine antimoniate: 31/56 (55.4) a	Meglumine antimoniate: 18/51 (35.3) a	Meglumine antimoniate: 31/49 (63.3) a

* Data presented as range, unless other measure is specified

** No lower age limit was reported

*** Mean (SD)

† Data available for 88 of 136 patients; y/o: years old

^a Proportion of cure was calculated by the reviewers, as authors reported treatment failure in the original manuscript.